The refinancing extends maturities and provides additional liquidity headroom, but the 9.500% coupon on the senior secured notes signals high credit spread. Monitor the company's next quarterly earnings for leverage trends and whether the increased debt capacity is deployed for acquisitions or share repurchases.
Price Chart
Executive Summary
Integra LifeSciences entered into a comprehensive refinancing on October 19, 2026, replacing its existing credit agreement with a new $1.65 billion credit facility and issuing $450 million of 9.500% senior secured notes due 2033. The new credit agreement includes a $600 million Term A loan, a $450 million Term B loan, and a $600 million revolving credit facility, all maturing in 2031-2033. Proceeds were used to repay the prior facility and for general corporate purposes. The transaction significantly extends the company's debt maturity profile and increases total leverage capacity.
Key Financial Metrics
Key Facts
- Entered into a new $1.65 billion credit facility: $600M Term A loan, $450M Term B loan, and $600M revolving credit facility
- Issued $450 million of 9.500% senior secured notes due 2033
- Refinanced and terminated the existing Seventh Amended and Restated Credit Agreement dated March 24, 2023
- Term A loan and revolving credit facility mature on October 19, 2031; Term B loan matures on October 19, 2033
- Term B loan carries interest at Term SOFR + 4.25% (or Base Rate + 3.25%)
- Term A loan and revolving credit facility carry interest at Term SOFR + 2.00%-3.25% depending on leverage ratio
- Financial covenants include maximum total leverage ratio (starting at 4.75x, stepping down to 4.00x) and minimum interest coverage ratio (2.75x-3.00x)
- Senior secured notes rank pari passu with the credit facility and are secured by the same collateral under a first-lien intercreditor agreement
- Proceeds used to refinance existing debt, pay fees and expenses, and for general corporate purposes
Financial Impact
Refinancing of approximately $1.05 billion in existing credit facilities with new $1.65 billion facility plus $450 million in senior secured notes, increasing total debt capacity by approximately $1.05 billion
Risk Factors
- Higher interest expense from the 9.500% senior secured notes could pressure earnings
- Increased total debt capacity may lead to future leverage-increasing acquisitions
- Financial covenants (max 4.00x leverage by March 2028) could constrain operations if EBITDA declines
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-425271 |
| Document: d142199dex41.htm | 0001193125-26-425271 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.13 (−2.41%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.13 (−9.04%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.13 (−10.38%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.13 (−7.97%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.13 (+13.27%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.13 (−8.97%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.13 (−25.43%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.13 (−13.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers